Rankings
▼
Calendar
CRDF FY 2024 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena
CRDF
Cardiff Oncology, Inc.
$139M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$683,000
+40.0% YoY
Gross Profit
$683,000
100.0% margin
Operating Income
-$49M
-7123.1% margin
Net Income
-$45M
-6651.7% margin
EPS (Diluted)
$-0.95
Cash Flow
Operating Cash Flow
-$38M
Free Cash Flow
-$38M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$97M
Total Liabilities
$14M
Stockholders' Equity
$83M
Cash & Equivalents
$51M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$683,000
$488,000
+40.0%
Gross Profit
$683,000
$488,000
+40.0%
Operating Income
-$49M
-$45M
-7.1%
Net Income
-$45M
-$41M
-9.6%
← Q4 2023
All Quarters
Q1 2024 →